Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET

Clinical Nuclear Medicine

Volumn 34, Issue 9, 2009, Pages 576-584

  Dimitrakopoulou Strauss, Antonia ^a   Hoffmann, Martin ^b   Bergner, Raoul ^b   Uppenkamp, Michael ^b   Haberkorn, Uwe ^a,c   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

F 18 FDG; Kinetic modeling; Multiple myeloma; Prognosis; Therapy monitoring

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; IDARUBICIN; TIOGUANINE; VINCRISTINE;

ARTICLE; BLOOD VOLUME; CANCER PATIENT; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; HUMAN; KINETICS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 70350099221     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181b06bc5     Document Type: Article

References (18)

1. Available at: http://www.multiplemyeloma.org/about-myeloma/index.html.
2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842-854.
3. Dimopoulos MA, Kastritis E, Anagnostopoulos A. Hematologic malignancies: myeloma. Ann Oncol. 2006;17:137-143.
4. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
5. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
6. Mikolajczyk K, Szabatin M, Rudnicki P, et al. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform. 1998;23:207-214.
7. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of short-term survival in patients with advanced non-small-cell lung cancer following chemotherapy based on 2-deoxy-2-(F-18)-fluoro-D-glucose positron emission tomography: a feasibility study. Mol Imaging Biol. 2007; 9:308-317.
8. Miyazawa H, Osmont A, Petit-Taboue MC, et al. Determination of 18Ffluoro- 2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263-272.
9. Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Wide'n L, eds. The Metabolism of the Human Brain Studied With Positron Emission Tomography. New York, NY: Raven Press; 1983:123-148.
10. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
11. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. On the fractal nature of positron emission tomography (PET) studies. World J Nucl Med. 2003;4: 306-313.
12. Schirrmacher H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:361-366.
13. Durie BG, Waxman AD, D'Agnolo A, et al. Whole-body 18F-FDG PET identifies high-risk myelomas. J Nucl Med. 2002;43:1457-1463.
14. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol. 2005;184: 1199-1204.
15. Dimitrakopoulou-Strauss A, Strauss LG. Quantitative studies using positron emission tomography for the diagnosis and therapy planning in oncological patients. Hell J Nucl Med. 2006;9:10-21.
16. Couturier O, Jerusalem G, N'Guyen JM, et al. Sequential positron emission tomography using (18F)fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12:6437-6443.
17. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002; 54:1024-1035.
18. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-1487.